OvaScience Inc (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced Paul W.D. Chapman has joined the Company as Chief Operating Officer. Mr. Chapman will be responsible for ensuring OvaScience’s treatments are available on a global commercial scale. He will serve on the executive management team of OvaScience and report to Dr. Michelle Dipp, M.D., Ph.D., Executive Chairman and Chief Executive Officer ofOvaScience.
“As OvaScience ramps up commercial activities in 2016, we are diversifying our team to complement our strong scientific expertise with commercial and operational experience,” said Michelle Dipp, M.D., Ph.D., Executive Chairman and Chief Executive Officer of OvaScience. “With decades of experience behind him, Paul has proven his ability to develop and implement strategies across sales, marketing and business development capacities to global life sciences companies. I’m excited for Paul to join our leadership team as we grow our business and continue to expand access to our fertility treatments in select international markets.”
Mr. Chapman joins from ArjoHuntleigh AB, a Sweden-based leading acute and long-term care equipment company with global revenues of approximately $1 billion, where he served as Regional President of North America. In this role, Mr. Chapman turned around ArjoHuntleigh’s caregiver equipment business for patients with reduced mobility and implemented a comprehensive post-merger integration plan following parent company Getinge AB’s acquisition of Kinetic Concepts, Inc. Prior to this role, Mr. Chapman served as President and CEO of Massachusetts-based diagnostic company Quanterix, where he oversaw growth including closing a global licensing deal with BioMérieux and a Series C financing round of more than $45 million. Over the course of his more than 20-year career, Mr. Chapman has also held executive leadership roles at EMD Millipore, where he was Vice President of the Company’s BioPharm Process Solutions business, and the Roche Group, where he held multiple roles across different business areas including Hospital Solutions for Roche Near Patient Testing, Roche Molecular Diagnostics and Roche Diagnostics Canada. Mr. Chapman holds a B.S. degree in Microbiology from the University of Western Ontario, a B.S. (hons) in Immunology from the University of Guelph Ontario and he graduated from the Marketing Management Program from the Richard Ivey School of Business. (Original Source)
Shares of OvaScience closed yesterday at $6.44. OVAS has a 1-year high of $55.69 and a 1-year low of $4.53. The stock’s 50-day moving average is $6.52 and its 200-day moving average is $12.15.
On the ratings front, OvaScience has been the subject of a number of recent research reports. In a report issued on February 16, H.C. Wainwright analyst Andrew Fein maintained a Buy rating on OVAS, with a price target of $15, which represents a potential upside of 132.9% from where the stock is currently trading. Separately, on January 25, Oppenheimer’s Rohit Vanjani downgraded the stock to Hold .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Andrew Fein and Rohit Vanjani have a total average return of -4.9% and 11.2% respectively. Fein has a success rate of 40.2% and is ranked #3189 out of 3666 analysts, while Vanjani has a success rate of 54.0% and is ranked #159.
OvaScience Inc is a life science company engaged in discovery, development, and commercialization of new fertility treatments. Its patented technology is based on egg precursor cells found in the outer layer of a woman’s own ovaries.